Edition:
United States

Veloxis Pharmaceuticals A/S (VELOX.CO)

VELOX.CO on Copenhagen Stock Exchange

1.06DKK
7:22am EDT
Change (% chg)

kr.-0.02 (-1.85%)
Prev Close
kr.1.08
Open
kr.1.08
Day's High
kr.1.08
Day's Low
kr.1.06
Volume
265,208
Avg. Vol
1,034,854
52-wk High
kr.1.45
52-wk Low
kr.1.03

Latest Key Developments (Source: Significant Developments)

Veloxis Pharmaceuticals H1 revenue $16.17 million
Wednesday, 16 Aug 2017 11:13am EDT 

Aug 16 (Reuters) - Veloxis Pharmaceuticals A/S ::Veloxis pharmaceuticals a/s says revenue reached $16.17 million in first half of 2017 representing an increase of 394% compared to same period last year.Veloxis pharmaceuticals a/s says reported a net loss of $4.25 million for first half of 2017 compared to a net loss of $16.4 million for same period in 2016..Veloxis narrows its 2017 outlook of operating loss before items from $ 5 million- $15 million to be in range of $10 million - $15 million.  Full Article

Veloxis Pharmaceuticals A/S, Endo Ventures enter deal to commercialize Envarsus XR in Canada
Tuesday, 6 Jun 2017 02:59pm EDT 

June 6 (Reuters) - Veloxis Pharmaceuticals A/S ::Veloxis Pharmaceuticals A/S and Endo Ventures Limited jointly announce agreement for Paladin Labs Inc. To commercialize Envarsus XR® in Canada.Initial term of agreement is 15 years from effective date of agreement.Under terms of deal, co will get up-front payment and veloxis will supply envarsus xr at a pre-specified transfer price​.  Full Article

Veloxis Pharmaceuticals signs deal with Chiesi Farmaceutici to commercialize Envarsus XR in China
Tuesday, 6 Jun 2017 01:00am EDT 

June 6 (Reuters) - VELOXIS PHARMACEUTICALS A/S :ANNOUNCES AGREEMENT WITH CHIESI FARMACEUTICI S.P.A. TO COMMERCIALIZE ENVARSUS XR IN CHINA.SUBSIDIARY VELOXIS PHARMACEUTICALS, INC., ENTERS EXCLUSIVE LICENSE, SUPPLY AND DISTRIBUTION DEAL.DEAL WITH CHIESI FARMACEUTICI TO REGISTER, COMMERCIALIZE AND DISTRIBUTE ENVARSUS XR IN CHINA AND TAIWAN.VELOXIS WILL RECEIVE AN UP-FRONT PAYMENT IN AMOUNT OF USD 6 MILLION AND A MILESTONE PAYMENT UPON APPROVAL.INITIAL TERM OF AGREEMENT IS FOR A PERIOD OF 15 YEARS FROM EFFECTIVE DATE OF AGREEMENT.  Full Article

Veloxis and Endo Ventures announce agreement on commercialization in Canada
Monday, 5 Jun 2017 02:55am EDT 

June 5 (Reuters) - VELOXIS PHARMACEUTICALS A/S ::VELOXIS PHARMACEUTICALS A/S AND ENDO VENTURES LIMITED JOINTLY ANNOUNCE AGREEMENT FOR PALADIN LABS INC. TO COMMERCIALIZE ENVARSUS XR® IN CANADA .‍VELOXIS WILL RECEIVE AN UP-FRONT PAYMENT AND WILL SUPPLY ENVARSUS XR AT A PRE-SPECIFIED TRANSFER PRICE​.‍INITIAL TERM OF AGREEMENT IS 15 YEARS FROM EFFECTIVE DATE OF AGREEMENT.​.  Full Article

Veloxis Pharmaceuticals Q1 operating loss narrows to $5.2 mln
Wednesday, 17 May 2017 01:23am EDT 

May 17 (Reuters) - VELOXIS PHARMACEUTICALS A/S ::SAID ON TUESDAY Q1 REVENUE $4.0 MLN VS $1.5 MLN YR AGO.Q1 OPERATING LOSS $5.2 MLN VS LOSS $6.9 MLN YR AGO .Q1 NET LOSS $5.9 MLN VS LOSS $7.1 MLN YR AGO.VELOXIS MAINTAINS ITS 2017 OUTLOOK OF OPERATING LOSS BEFORE THE RECOGNITION OF INCOME FROM LICENSE AGREEMENTS AND BEFORE ACCOUNTING FOR STOCK COMPENSATION TO BE IN THE RANGE OF USD 5 – 15 MILLION..  Full Article

Veloxis increases share capital in connection with exercise of warrants
Tuesday, 4 Apr 2017 01:00am EDT 

VELOXIS PHARMACEUTICALS A/S : CAPITAL INCREASED BY 1,000,000 NEW SHARES WITH A NOMINAL VALUE OF DKK 0.10 EACH CORRESPONDING TO NOMINALLY DKK 100,000 AS A CONSEQUENCE OF EXERCISE OF WARRANTS .AS A RESULT OF EMPLOYEE'S INVESTMENT IN COMPANY PROCEEDS TO VELOXIS PHARMACEUTICALS A/S FROM CAPITAL INCREASE AMOUNTS TO DKK 350,000.  Full Article

Veloxis Pharmaceuticals announces New Jersey office closure
Tuesday, 28 Feb 2017 09:30am EST 

Veloxis Pharmaceuticals A/S : US subsidiary, Veloxis Pharmaceuticals Inc., has decided to close its office in Edison, New Jersey effective February 28, 2017 .All of the company’s operations will now be based out of its Cary, North Carolina office.  Full Article

Veloxis Pharmaceuticals announces amended and restated loan and security agreement
Wednesday, 8 Feb 2017 05:07am EST 

Veloxis Pharmaceuticals A/S : Agreed to amend and restate terms of its previously announced loan and security agreement with Lundbeckfond Invest A/S and Novo A/S. .Terms of amended and restated agreement make available an additional $10 million in financing at an interest rate of 12 pct, payable annually in arrears.  Full Article

Veloxis Q3 net loss narrows to $7.6 million
Wednesday, 16 Nov 2016 09:00am EST 

Veloxis Pharmaceuticals A/S : Q3 net revenue $2.2 million versus $1.8 million in Q2 and $0.5 million year ago . Q3 net loss $7.6 million versus loss $9.3 million in Q2 and loss $7.2 million year ago .Maintains its 2016 outlook of operating loss and net loss of $25.0 - 31.0 million.  Full Article

Veloxis Pharmaceuticals Q2 operating loss widens to $9.6 million
Thursday, 25 Aug 2016 01:33am EDT 

Veloxis Pharmaceuticals A/S : Said on Wednesdays Q2 revenue $1.8 million versus $783,000 year ago . Q2 operating loss $9.6 million versus loss $5.3 million year ago . Q2 pre-tax loss $9.3 million versus loss $6.0 million year ago .Has revised 2016 outlook to operating loss and net loss of $25.0 million – $31.0 million (previously reported $17.6 million – $23.4 million).  Full Article

BRIEF-Veloxis Pharmaceuticals H1 revenue $16.17 million

* Veloxis pharmaceuticals a/s says revenue reached $16.17 million in first half of 2017 representing an increase of 394% compared to same period last year